Menu Search
Equities

Novartis AG

NVS:NYQ

Novartis AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)103.85
  • Today's Change0.76 / 0.74%
  • Shares traded1.53m
  • 1 Year change+7.75%
  • Beta0.5692
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold9
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Novartis AG (ADR) have a median target of 120.00, with a high estimate of 130.00 and a low estimate of 97.00. The median estimate represents a 15.55% increase from the last price of 103.85.
High25.2%130.00
Med15.6%120.00
Low-6.6%97.00

Dividends in USD

In 2023, Novartis AG reported a dividend of 3.50 USD, which represents a 5.22% increase over last year. The 13 analysts covering the company expect dividends of 3.77 USD for the upcoming fiscal year, an increase of 7.70%.
Div growth (TTM)5.22%
More ▼

Earnings history & estimates in USD

On Oct 29, 2024, Novartis AG (ADR) reported 3rd quarter 2024 earnings of 2.06 per share. This result exceeded the 1.96 consensus of the 7 analysts covering the company and exceeded last year's 3rd quarter results by 12.57%.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+3.82%
Novartis AG (ADR) reported annual 2023 earnings of 6.90 per share on Jan 31, 2024.
Average growth rate+6.48%
More ▼

Revenue history & estimates in USD

Novartis AG (ADR) had 3rd quarter 2024 revenues of 12.82bn. This bettered the 12.76bn consensus of the 8 analysts covering the company. This was 1.00% below the prior year's 3rd quarter results.
Average growth rate+2.19%
Novartis AG (ADR) had revenues for the full year 2023 of 45.44bn. This was 10.10% below the prior year's results.
Average growth rate-0.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.